Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nitrofurantoin is active against vancomycin-resistant enterococci.

G G Zhanel1, D J Hoban, J A Karlowsky

  • 1Departments of Clinical Microbiology and Medicine, Health Sciences Centre and Faculties of Medicine and Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada. ggzhanel@pcs.mb.ca

Antimicrobial Agents and Chemotherapy
|December 20, 2000
PubMed
Summary

Nitrofurantoin effectively combats common enterococci, including vancomycin-resistant strains. This antibiotic shows promise for treating urinary tract infections caused by these challenging pathogens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021).

Diagnostic microbiology and infectious disease·2023
Same author

Presence of the narrow-spectrum OXA-1 β-lactamase enzyme is associated with elevated piperacillin/tazobactam MIC values among ESBL-producing <i>Escherichia coli</i> clinical isolates (CANWARD, 2007-18).

JAC-antimicrobial resistance·2022
Same author

Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential.

The Journal of antimicrobial chemotherapy·2017
Same author

In vitro activity of tigecycline and comparators against carbapenem-resistant Enterobacteriaceae in Africa-Middle East countries: TEST 2007-2012.

Journal of global antimicrobial resistance·2016
Same author

Integrated pharmacokinetic-pharmacodynamic modelling to evaluate antimicrobial prophylaxis in abdominal surgery.

The Journal of antimicrobial chemotherapy·2016
Same author

Epidemiology of vancomycin-resistant enterococci in Canadian hospitals (CANWARD study, 2007 to 2013).

Antimicrobial agents and chemotherapy·2015

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Pharmacology

Background:

  • Enterococcus species, including Enterococcus faecium, Enterococcus faecalis, and Enterococcus gallinarum, are significant causes of healthcare-associated infections.
  • The rise of vancomycin-resistant enterococci (VRE) poses a therapeutic challenge, particularly for urinary tract infections (UTIs).

Purpose of the Study:

  • To evaluate the in vitro activity of nitrofurantoin against a diverse collection of enterococcal isolates.
  • To determine if vancomycin resistance influences susceptibility to nitrofurantoin.

Main Methods:

  • Antimicrobial susceptibility testing was performed on 300 enterococcal isolates.
  • Minimum Inhibitory Concentrations (MICs) for nitrofurantoin were determined.
  • Isolates included vancomycin-resistant Enterococcus faecium (VREfm) with vanA and vanB genes and vancomycin-resistant Enterococcus gallinarum.

Related Experiment Videos

Main Results:

  • All 300 enterococcal isolates, including VREfm and vancomycin-resistant E. gallinarum, were susceptible to nitrofurantoin.
  • No nitrofurantoin resistance was observed, with MICs consistently high (>/=128 microg/ml).

Conclusions:

  • Nitrofurantoin demonstrates potent in vitro activity against clinically relevant Enterococcus species.
  • Nitrofurantoin represents a potential therapeutic option for UTIs caused by vancomycin-resistant enterococci.